Venom-Induced Blood Disturbances by Palearctic Viperid Snakes, and Their Relative Neutralization by Antivenoms and Enzyme-Inhibitors
Open Access
- 10 June 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Abstract
Palearctic vipers are medically significant snakes in the genera Daboia, Macrovipera, Montivipera, and Vipera which occur throughout Europe, Central Asia, Near and Middle East. While the ancestral condition is that of a small-bodied, lowland species, extensive diversification has occurred in body size, and niche specialization. Using 27 venom samples and a panel of in vitro coagulation assays, we evaluated the relative coagulotoxic potency of Palearctic viper venoms and compared their neutralization by three antivenoms (Insoserp Europe, VIPERFAV and ViperaTAb) and two metalloprotease inhibitors (prinomastat and DMPS). We show that variation in morphology parallels variation in the Factor X activating procoagulant toxicity, with the three convergent evolutions of larger body sizes (Daboia genus, Macrovipera genus, and Vipera ammodytes uniquely within the Vipera genus) were each accompanied by a significant increase in procoagulant potency. In contrast, the two convergent evolutions of high altitude specialization (the Montivipera genus and Vipera latastei uniquely within the Vipera genus) were each accompanied by a shift away from procoagulant action, with the Montivipera species being particularly potently anticoagulant. Inoserp Europe and VIPERFAV antivenoms were both effective against a broad range of Vipera species, with Inoserp able to neutralize additional species relative to VIPERFAV, reflective of its more complex antivenom immunization mixture. In contrast, ViperaTAb was extremely potent in neutralizing V. berus but, reflective of this being a monovalent antivenom, it was not effective against other Vipera species. The enzyme inhibitor prinomastat efficiently neutralized the metalloprotease-driven Factor X activation of the procoagulant venoms. In contrast, DMPS (2,3-dimercapto-1-propanesulfonic acid), which as been suggested as another potential treatment option in the absence of antivenom, DMPS failed against all venoms tested. Overall, our results highlight the evolutionary variations within Palearctic vipers and help to inform clinical management of viper envenomation.Keywords
This publication has 74 references indexed in Scilit:
- Comparison of Phylogeny, Venom Composition and Neutralization by Antivenom in Diverse Species of Bothrops ComplexPLOS Neglected Tropical Diseases, 2013
- A phylogeny and revised classification of Squamata, including 4161 species of lizards and snakesBMC Ecology and Evolution, 2013
- New approaches for unravelling reassortment pathwaysBMC Ecology and Evolution, 2013
- Venomous snakebites in the Croatian North Dalmatia regionWiener klinische Wochenschrift, 2011
- Antivenoms for the treatment of snakebite envenomings: The road aheadBiologicals, 2011
- Failure of antivenom to improve recovery in Australian snakebite coagulopathyQJM: An International Journal of Medicine, 2009
- Reappraisal of Vipera aspis Venom NeurotoxicityPLOS ONE, 2007
- Second-degree heart block associated with envenomation by Vipera berus.Emergency Medicine Journal, 1988
- Recovery from Multiple Bites by Vipera Xanthina PalestinaeClinical Pediatrics, 1982
- The Action of Vipern Xanthina Palestinae Venom on Blood Coagulation in VitroBritish Journal of Haematology, 1957